Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes

Journal of Interferon and Cytokine Research

Volumn 31, Issue 6, 2011, Pages 475-479

  Scagnolari, Carolina ^a   Trombetti, Simona ^a   Soldà, Annalisa ^a   Selvaggi, Carla ^a   Monteleone, Katia ^a   Spano, Lucia ^a   Pierangeli, Alessandra ^a   Clementi, Massimo ^b   Turriziani, Ombretta ^a   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON 1; ALPHA INTERFERON 10; ALPHA INTERFERON 14; ALPHA INTERFERON 17; ALPHA INTERFERON 2; ALPHA INTERFERON 21; ALPHA INTERFERON 5; ALPHA INTERFERON 7; ALPHA INTERFERON 8; ALPHA INTERFERON DERIVATIVE; BETA INTERFERON; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; INNATE IMMUNITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTERFERON TYPE I, RECOMBINANT; PANDEMICS; RESPIRATORY MUCOSA; VIRUS REPLICATION;

ENCEPHALOMYOCARDITIS VIRUS; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 79958190181     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2010.0125     Document Type: Article

References (34)

1. Antonelli G. 2008. Biological basis for a proper clinical application of alpha interferons. New Microbiol 31(3):305-318.
2. Ariyasu T, Tanaka T, Fujioka N, Yanai Y, Yamamoto S, Ya-mauchi H, Ikegami H, Ikeda M, Kurimoto M. 2005. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. In Vitro Cell Dev Biol Anim 41(1-2):50-56. (Pubitemid 40791632)
3. Billharz R, Zeng H, Proll SC, Korth MJ, Lederer S, Albrecht R, Goodman AG, Rosenzweig E, Tumpey TM, Garćýa-Sastre A, Katze MG. 2009. The NS1 protein of the 1918 pandemic influenza virus blocks host interferon and lipid metabolism pathways. Virology 83(20):10557-10570.
4. Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, De Marco D, Saita D, Diotti RA, Sautto G, Sampaolo M, Clementi M. 2009. Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol 32(4):319-324.
5. Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM. 2003. Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101(7):2727-2735. (Pubitemid 36857636)
6. Dianzani F, Capobianchi MR, Antonelli G, Amicucci P, De Marco F. 1989. Susceptibility of human immunodeficiency virus to antiviral agents measured by infectious virus yield reduction. Antiviral Res 11(5-6):299-305.
7. Dittmann J, Stertz S, Grimm D, Steel J, Garćýa-Sastre A, Haller O, Kochs G. 2008. Influenza A virus strains differ in sensitivity to the antiviral action of Mx-GTPase. J Virol 82(7): 3624-3631. (Pubitemid 351429938)
8. Echevarrý́a-Zuno S, Mej́ýa-Aranguré JM, Mar-Obeso AJ, Grajales-Muñiz C, Robles-Pérez E, González-León M, Ortega-Alvarez MC, Gonzalez-Bonilla C, Rascón-Pacheco RA, Borja-Aburto VH. 2009. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374:2072-2079.
9. Foster GR, Finter NB. 1998. Are all type I human interferons equivalent? J Viral Hepat 5(3):143-152. (Pubitemid 28374722)
10. Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, de Dios C, Sizing I, James MJ, Marelli-Berg FM. 2004. IFN-alpha subtypes differentially affect human T cell motility. J Immunol 173(3):1663-1670. (Pubitemid 38971597)
11. Garćýa-Sastre A. 2006. Antiviral response in pandemic influenza viruses. Emerg Infect Dis 12(1):44-47. (Pubitemid 43143534)
12. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr., Boxrud D, Sambol AR, Abid SH, St. George K, Ban-nerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
13. Hale BG, Randall RE, Ort́ýn J, Jackson D. 2008. The multifunctional NS1 protein of influenza A viruses. J Gen Virol 89(10):2359-2376.
14. Haller O, Staeheli P, Kochs G. 2009. Protective role of interferon-induced Mx GTPases against influenza viruses. Rev Sci Tech 28(1):219-231.
15. Haller O, Weber F. 2007. Pathogenic viruses: smart manipulators of the interferon system. Curr Top Microbiol Immunol 316:315-334.
16. Hilkens CM, Schlaak JF, Kerr IM. 2003. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 171(10):5255-5263. (Pubitemid 37432810)
17. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe Y, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Ya-mashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Ka-waoka Y. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460(7258):1021-1025.
18. Jaks E, Gavutis M, Uzé G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366(2):525-539. (Pubitemid 46136210)
19. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325(5939):484-487.
20. Mitchell H, Levin D, Forrest S, Beauchemin CA, Tipper J, Knight J, Donart N, Layton RC, Pyles J, Gao P, Harrod KS, Perelson AS, Koster F. 2010. Higher replication efficiency of 2009 (H1N1) pandemic influenza than seasonal and avian strains: kinetics from epithelial cell culture and computational modeling. J Virol [Epub ahead of print]; DOI: 10.1128/JVI.01722-10.
21. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Günther S, Drosten C, Michiels T, Staeheli P. 2010. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84(11):5670-5677.
22. Neumann G, Noda T, Kawaoka Y. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939.
23. Osterlund P, Pirhonen J, Ikonen N, Rönkkö E, Strengell M, Mäkelä SM, Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I. 2010. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol 84(3):1414-1422.
24. Peiris JS, Poon LL, Guan Y. 2009. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 45:169-173.
25. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent and-points. Am J Hyg 27:493-497.
26. Rhodes J, Ivanyi J, Cozens P. 1986. Antigen presentation by human monocytes: effects of modifying major histocompati-bility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticoste-roids. Eur J Immunol 16(4):370-375. (Pubitemid 16104517)
27. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G. 2004. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 9(6):1003-1011. (Pubitemid 40040274)
28. Seo SH, Hoffmann E, Webster RG. 2002. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 8(9):950-954. (Pubitemid 35033698)
29. Taubenberger JK. 2005. The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Arch Virol Suppl (19):101-115.
30. Uzé G, Lutfalla G, Mogensen KE. 1995. Alpha and beta inter-ferons and their receptor and their friends and relations. J Interferon Cytokine Res 15(1):3-26.
31. Verhagen A, Mackay IR, Rowley M, Tymms M. 1990. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul 9(5):325-333.
32. Wolff T, Ludwig S. 2009. Influenza viruses control the vertebrate type I interferon system: factors, mechanisms, and consequences. J Interferon Cytokine Res 29(9):549-557.
33. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chot-pitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362(18):1708-1719.
34. Yamaoka T, Kojima S, Ichi S, Kashiwazaki Y, Koide T, Sokawa Y. 1999. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells. J Interferon Cytokine Res 19(12):1343-1349. (Pubitemid 30032936)